JP2006511495A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511495A5
JP2006511495A5 JP2004548497A JP2004548497A JP2006511495A5 JP 2006511495 A5 JP2006511495 A5 JP 2006511495A5 JP 2004548497 A JP2004548497 A JP 2004548497A JP 2004548497 A JP2004548497 A JP 2004548497A JP 2006511495 A5 JP2006511495 A5 JP 2006511495A5
Authority
JP
Japan
Prior art keywords
heterocycle
aryl
alkyl
pharmaceutical composition
occurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004548497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511495A (ja
Filing date
Publication date
Priority claimed from US10/693,793 external-priority patent/US20040087642A1/en
Application filed filed Critical
Publication of JP2006511495A publication Critical patent/JP2006511495A/ja
Publication of JP2006511495A5 publication Critical patent/JP2006511495A5/ja
Pending legal-status Critical Current

Links

JP2004548497A 2002-10-24 2003-10-24 疼痛の治療、予防、管理および／または改善のためのｊｎｋ阻害剤の使用方法およびそれを含む組成物 Pending JP2006511495A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42110402P 2002-10-24 2002-10-24
US10/693,793 US20040087642A1 (en) 2002-10-24 2003-10-23 Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
PCT/US2003/034006 WO2004039325A2 (en) 2002-10-24 2003-10-24 Treatment of pain with jnk inhibitors

Publications (2)

Publication Number Publication Date
JP2006511495A JP2006511495A (ja) 2006-04-06
JP2006511495A5 true JP2006511495A5 (https=) 2006-11-24

Family

ID=32179841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004548497A Pending JP2006511495A (ja) 2002-10-24 2003-10-24 疼痛の治療、予防、管理および／または改善のためのｊｎｋ阻害剤の使用方法およびそれを含む組成物

Country Status (11)

Country Link
US (1) US20040087642A1 (https=)
EP (1) EP1553951A4 (https=)
JP (1) JP2006511495A (https=)
KR (1) KR20050057673A (https=)
AU (1) AU2003284980B2 (https=)
BR (1) BR0315573A (https=)
CA (1) CA2503616A1 (https=)
MX (1) MXPA05004180A (https=)
NZ (1) NZ540027A (https=)
TW (1) TW200418460A (https=)
WO (1) WO2004039325A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
AU2004283716A1 (en) * 2003-10-24 2005-05-06 Celgene Corporation Methods and compositions comprising thalidomide for treatment of fibromyalgia
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
ZA200704889B (en) * 2004-11-23 2008-09-25 Celgene Corp JNK inhibitors for treatment of CNS injury
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
WO2008024776A1 (en) * 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting jnk signaling promotes cns axon regeneration
MX2009006313A (es) * 2006-12-13 2009-06-23 Organon Nv Antagonistas v3 para el tratamiento o prevencion de dolor cronico.
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
MX2009013213A (es) * 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
EP2184987A4 (en) * 2007-07-31 2011-09-28 Burnham Inst Medical Research BIDENTATE COMPOUNDS AS KINASEHEMMER
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
WO2011160653A1 (en) * 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
BR112013015460B1 (pt) * 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
WO2012178022A2 (en) * 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
WO2021067749A2 (en) * 2019-10-02 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095415A (en) * 1958-05-30 1963-06-25 Ciba Ltd Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group
CH428043A (fr) * 1965-08-16 1967-01-15 Sandoz Ag Procédé de fabrication de colorants de dispersion isothiazolantroniques
US3541110A (en) * 1967-01-20 1970-11-17 American Home Prod Indazole-5-sulfonamides
JPS63184364A (ja) * 1987-01-27 1988-07-29 Toshiba Corp 半導体装置の製造方法
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
US5434136A (en) * 1990-12-14 1995-07-18 Mathias; John R. Treatment of motility disorders with a GNRH analog
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CN1137680C (zh) * 1995-09-19 2004-02-11 藤泽药品工业株式会社 气雾剂组合物
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
AU6870098A (en) * 1997-03-31 1998-10-22 Du Pont Merck Pharmaceutical Company, The Indazoles of cyclic ureas useful as hiv protease inhibitors
US6258819B1 (en) * 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
BR0013551A (pt) * 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
KR20080028516A (ko) * 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
AU7349301A (en) * 2000-07-21 2002-02-05 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
WO2002083083A2 (en) * 2001-03-30 2002-10-24 King Pharmaceuticals, Inc. Pharmaceutically active compounds and methods of use
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
US6562033B2 (en) * 2001-04-09 2003-05-13 Baylis Medical Co. Intradiscal lesioning apparatus
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
GB0112494D0 (en) * 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
GB0115182D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Medicaments
BR0212760A (pt) * 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
WO2003075917A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers

Similar Documents

Publication Publication Date Title
JP2006511495A5 (https=)
US6348481B2 (en) Pharmaceutical composition for angiotensin II-mediated diseases
EA200501075A1 (ru) Лекарственное средство для профилактики и лечения артериосклероза и гипертензии
MA30967B1 (fr) Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
JP2003528917A5 (https=)
JP2010523477A5 (https=)
JP2017504611A (ja) 組合せ医薬
WO2006047195A3 (en) 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP2002533406A (ja) 新生物の治療における併用療法として、金属プロティナーゼ抑制剤および一またはそれ以上の抗新生物剤を用いる方法
WO2018049027A1 (en) Combination therapies using immuno-dash inhibitors and pge2 antagonists
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
RU2013138569A (ru) Антагонисты рецептора минералокортикоидов
JP2003535061A (ja) エンドセリン受容体拮抗剤および疼痛軽減特性を有する抗癲癇化合物または鎮痛剤の複合物
CA2409741A1 (en) Tnf-.alpha. production inhibitors
MA30704B1 (fr) Compositions therapeutiques
CZ235193A3 (en) Pharmaceutical preparation containing antagonist of angiotensin-ii receptor and calcium channels blocking compound
JP2004523569A (ja) 抗高血圧薬とコレステロール吸収阻害薬の併用療法
CN101384257A (zh) 药物组合
ES2274234T3 (es) 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
JP2005535594A5 (https=)
ES2287520T3 (es) Agonistas de los receptores de 5-ht 1b/1d para el tratamiento de cefalea producida por la administracion de un antagonista del receptor de endotelina.
RU2007116987A (ru) Новые соединения
RU2010128542A (ru) Производные 3-карбоксипропил-аминотетралина и родственные соединения в качестве антагонистов mu-опиоидного рецептора
JP2006507307A5 (https=)